Entropy CEO Jason Carroll said, “The DSMB’s recommendation to progress to Cohort 2 without any protocol changes is an important milestone for the TRP-8803 program and provides independent validation of the favourable safety profile observed in Cohort 1.”

Memphasys has announced a 12-month exclusive national supply agreement with Monash IVF Group for the Felix automated sperm selection system.

The survey found that 82 per cent of biotech companies six years and older agreed they would experience a significant impact. 36 respondents (61 per cent) said the proposed changes to the Capital Gains Tax would negatively affect them.

Andy Wong, Head of Innovation and Technology (Life and Health Sciences) at InvestHK, recently returned to Hong Kong after attending the AusMedtech Conference in Perth.

Prescient Therapeutics has announced that Dr Rosalind Wilson will become its Chief Medical Officer, a move the clinical-stage oncology company says will strengthen its clinical and strategic capabilities as it advances multiple programs.

Australian cell therapy company Cartherics has announced that the Japanese Patent Office has issued a new patent for its off-the-shelf immune cell therapies.

CEO and Managing Director Dr David Foster said, “The expansion of our CRADA with USAMRIID and Geneva represents a major strategic milestone for Island and positions the Company to undertake the efficacy study prior to the pivotal study for Galidesivir.”

“We want to work with the Government to get these policy settings right and at speed so we can give Australia’s biotech, medtech and health tech companies the policy certainty they need to continue to thrive. We just need Government to meet us at the table,” said AusBiotech CEO Rebekah Cassidy.

Alterity Therapeutics has announced that the US Food and Drug Administration has agreed on the key design elements for a pivotal Phase 3 trial of ATH434 in Multiple System Atrophy following a successful End of Phase 2 meeting.

The company said the FDA correspondence represents a significant regulatory milestone because it completes the substantive review and moves the filing to the last administrative step before a decision.

LTR Pharma has taken a decisive step toward bringing its rapid-acting intranasal erectile dysfunction treatment ROXUS to the United States by signing a binding term sheet with Shed Holdings, a US direct-to-consumer telehealth platform.

Researchers at the Snow Centre for Immune Health have uncovered subtle but consistent differences in immune cell behaviour in people with coeliac disease, suggesting risk may arise from how the immune system functions long before symptoms appear.

The forum, running since 2018, gives early-stage innovators the chance to pitch to a panel of industry experts and receive feedback that helps move projects and technologies toward commercialisation, one of AusBiotech’s key efforts to support start-ups and SMEs on their commercial journeys.

Opthea has announced its reinstatement to the ASX and unveiled a sharply refocused strategy centred on advancing OPT-302 for lymphangioleiomyomatosis, or LAM, a rare pulmonary disease with significant unmet need.

Nyrada has completed a pilot preclinical study testing repeated subcutaneous dosing of its lead candidate Xolatryp in combination with the chemotherapy drug doxorubicin.

Island Pharmaceuticals has announced it is advancing GMP manufacturing of its antiviral, Galidesivir, to support a pivotal Marburg study under the US FDA Animal Rule pathway.

Executive Chair Dr Pete Smith said, “The support from our shareholders is deeply appreciated. Achieving a 97 per cent conversion rate is a remarkable outcome and an endorsement of our clinical development program for RC220."